Bae, S.H., Heo, J., Kim, C., Kim, T.W., Shin, J.Y., Lee, J.Y., Song, S.J., Park, T.K., Moon, S.W. and Chung, H. (2014) Low-Fluence Photodynamic Therapy versus Ranibizumab for Chronic Central Serous Chorioretinopathy. Ophthalmology, 121, 558-565.
http://dx.doi.org/10.1016/j.ophtha.2013.09.024

has been cited by the following article:

• TITLE: Intravitreal Bevacizumab for the Treatment of Chronic or Recurrent Central Serous Chorioretinopathy

  AUTHORS: Mitzy E. Torres Soriano, Gerardo García Aguirre, Maximiliano Gordon Angelozzi, Veronica Kon Jara, Jans Fromow Guerra, Michael D. Ober, Hugo Quiroz Mercado

  KEYWORDS: Central Serous Chorioretinopathy, Intravitreal Bevacizumab, Retinal Pigment Epithelium Detachment

  JOURNAL NAME: Open Journal of Ophthalmology, Vol.4 No.3, July 24, 2014

  ABSTRACT: Background: We report the use of intravitreal bevacizumab as an option for the treatment of chronic or recurrent central serous chorioretinopathy (CSC). Methods: Eight eyes with chronic or recurrent CSC received intravitreal bevacizumab (1.25 mg/0.05 cc) and underwent best corrected visual acuity (VA), optical coherent tomography (OCT), fluorescein angiography (FA) and indocyanine green angiography (ICG) before, and one, three and six months after treatment. Results: All patients showed improvement in visual acuity, fluorescein angiographic leakage, choroidal hyperpermeability and reduced or resolved neurosensory detachment following treatment. Two patients require a second dose of intravitreal bevacizumab. Conclusions: Intravitreal injection of bevacizumab was associated with visual improvement and reduced neurosensory detachment without adverse events in patients with chronic or recurrent CSC. Although these results are promising, further investigations would be helpful to understand this therapy for patients with CSC.